These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 19573090

  • 1. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
    Doria C, Ramirez CB, Frank AM, Vaccino S, Fraser N, Marino IR.
    Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [Abstract] [Full Text] [Related]

  • 3. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
    Sterneck M, Settmacher U, Ganten T, Sarrazin C, Speidel N, Broering D, Heyne N, Paulus E, Mertens M, Fischer L.
    Transplant Proc; 2014 Nov; 46(1):234-40. PubMed ID: 24507058
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
    Lopez-Solis R, DeVera M, Steel J, Fedorek S, Sturdevant M, Hughes C, Humar A.
    Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
    Langone AJ, Chan L, Bolin P, Cooper M.
    Transplantation; 2011 Feb 27; 91(4):470-8. PubMed ID: 21245794
    [Abstract] [Full Text] [Related]

  • 11. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, Dakshinamurthy KV, Vijaykumar R, Abraham G, Bhaskar S, Agarwal L, Shah B, Abraham A, John M, Sampathkumar K, Das T, Umesh L, Sundar S, Ballal H, Jasuja S, Saxena S, Saha TK.
    Transplant Proc; 2008 Sep 27; 40(7):2262-7. PubMed ID: 18790208
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M, Bertoni E, Budde K, Holzer H, Civati G, Lien B, Arns W.
    Transplant Proc; 2010 May 27; 42(4):1325-8. PubMed ID: 20534293
    [Abstract] [Full Text] [Related]

  • 15. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
    Martinez-Mier G, Salazar-Ramirez A.
    Transplant Proc; 2016 Mar 27; 48(2):588-95. PubMed ID: 27110009
    [Abstract] [Full Text] [Related]

  • 16. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS.
    Transplantation; 2009 Aug 27; 88(4):514-20. PubMed ID: 19696634
    [Abstract] [Full Text] [Related]

  • 17. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M, Girón F, Hernández E, Juarez F, Liendo C, Novoa P, Toledo M, Myproms Latam Study Group.
    Transplant Proc; 2004 Aug 27; 36(6):1647-9. PubMed ID: 15350440
    [Abstract] [Full Text] [Related]

  • 18. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F, Rosich E, Arias M, Torregrosa V, Oppenheimer F, Campistol JM.
    Transplant Proc; 2007 Sep 27; 39(7):2179-81. PubMed ID: 17889130
    [Abstract] [Full Text] [Related]

  • 19. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.
    Barrera-Pulido L, Alamo-Martínez JM, Marín-Gómez LM, Suárez-Artacho G, Bernal-Bellido C, Domínguez-Usero D, Tallón-Aguilar L, Pareja-Ciuró F, Sousa-Martín JM, García-González I, Gómez-Bravo MA.
    Transplant Proc; 2009 Sep 27; 41(6):2192-4. PubMed ID: 19715870
    [Abstract] [Full Text] [Related]

  • 20. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.